S. aureus ImmuneSelect Peptide Pool Premium
Available in stock
Scientific China
StorePeople Also Viewed
-
Zika Virus ImmuneSelect Peptide Pool Premium
-
Yellow Fever Virus ImmuneSelect Peptide Pool Premium
-
West Nile Virus ImmuneSelect Peptide Pool Premium
-
VZV ImmuneSelect Peptide Pool Premium
-
TBEV ImmuneSelect Peptide Pool Premium
-
SARS-Cov-2 ImmuneSelect Peptide Pool Premium
-
SARS-Cov-2 (Omicron) ImmuneSelect Peptide Pool Premium
-
S. pneumoniae ImmuneSelect Peptide Pool Premium
-
Rubella Virus ImmuneSelect Peptide Pool Premium
-
RSV ImmuneSelect Peptide Pool Premium
| Catalog number | 1330-07 |
|---|---|
| Product category | Peptide Pools |
Product Enquiry
Description
S. aureus ImmuneSelect Peptide Pool Premium
Product overview
Staphylococcus aureus (S. aureus) ImmuneSelect peptide pool is composed of 38 peptides derived from the following proteins:
Thermonuclease (UniProt: Q2G010)
Staphylokinase (UniProt: Q2FWV3)
Staphylococcal superantigen-like 7 (UniProt: Q2G2Y0)
The peptides include both MHC-II epitopes and the purity of each peptide is ≥90% (HPLC-MS).
Key product information
The S. aureus ImmuneSelect Peptide Pool Premium is supplied by Virax Biolabs under catalog number 1330-07. It is categorized as Peptide Pools and is intended for research use according to the applicable product documentation.
Research applications
Suitable for in vitro immune-response studies and T-cell stimulation research workflows. Confirm protocol requirements, sample compatibility, and intended use before ordering.
Technical specifications
| Catalog number | 1330-07 |
|---|---|
| Product category | Peptide Pools |
Ordering and configuration
Contact Scientific China for availability, pack size or configuration options, minimum order quantity, lead time, and a formal quotation for the S. aureus ImmuneSelect Peptide Pool Premium.
Reviews (0)
Only logged in customers who have purchased this product may leave a review.

















































































Reviews
There are no reviews yet.